Rapid Micro Biosystems

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company. It provides mission critical automation solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus in 2006 and is headquartered in Lowell, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Rapid Micro Biosystems surpasses Q1 revenue targets, eyes global expansion

Rapid Micro Biosystems delivered a strong Q1 performance, exceeding revenue guidance and setting new records in consumable sales.
The company's focus on product innovation and customer-centric solutions positions it well for sustained growth and market expansion.
While challenges in revenue targets and margin improvements exist, strategic planning and operational enhancements offer opportunities for future success.

Rapid Micro Biosystems reports strong Q2 growth and cost-saving initiatives

Rapid Micro Biosystems showcased robust revenue growth and margin improvement in Q2 2024, driven by successful customer engagement and product placements.
While challenges like net losses persist, the company's proactive cost management and revenue outlook reaffirmation signal a commitment to financial health.
Opportunities lie in achieving positive cash flow by 2027, sustained revenue growth, and operational efficiency enhancements for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapid Micro Biosystems, Inc. is a life sciences technology company. It provides automated solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus on December 29, 2006 and is headquartered in Lexington, MA.

LOWELL, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

Rapid Micro Biosystems to Participate in the Virtual Gilmartin Group Emerging Growth Company Showcase

LOWELL, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference.

Rapid Micro Biosystems to Participate in the Morgan Stanley 21st Annual Global HealthCare Conference

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q2 2023 Earnings Call Transcript August 4, 2023 8:30 AM ET Company Participants Mike Beaulieu - Vice President of Investor Relations Rob Spignesi - CEO, President and Director Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Operator Ladies and gentlemen, thank you for standing by, and welcome to Rapid Micro Biosystems' Q2 2023 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Mike Beaulieu.

Rapid Micro Biosystems, Inc. (RPID) Q2 2023 Earnings Call Transcript

Reports second quarter 2023 total revenue of $5.0 million , representing growth of 30% compared to second quarter 2022

Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results

LOWELL, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second-quarter 2023 financial results prior to the market open on Friday, August 4, 2023.

Rapid Micro Biosystems to Announce Second Quarter 2023 Financial Results on August 4, 2023

LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the “Board”). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee.

Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors

Rapid Micro Biosystems, Inc. (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rapid Micro Biosystems, Inc. (RPID) Moves to Buy: Rationale Behind the Upgrade

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Mike Beaulieu - Investor Relations Rob Spignesi - President and Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Operator Good morning, and welcome to the Rapid Micro Biosystems First Quarter Financial Results Call. All lines have been placed on mute to prevent any background noise.

Rapid Micro Biosystems, Inc. (RPID) Q1 2023 Earnings Call Transcript

Reports first quarter 2023 total revenue of $5.0 million , representing growth of 21% , compared to first quarter 2022

Rapid Micro Biosystems Reports First Quarter 2023 Financial Results

LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing.

Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing

LOWELL, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2023 financial results prior to the market open on Friday, May 5, 2023.

Rapid Micro Biosystems to Announce First Quarter 2023 Financial Results on May 5, 2023

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q4 2022 Results Conference Call March 3, 2023 8:30 AM ET Company Participants Mike Beaulieu - VP, IR & Corporate Communications Rob Spignesi - President, CEO Sean Wirtjes - CFO Conference Call Participants Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JP Morgan Stephanie Yan - Cowen Operator Good morning, and welcome to Rapid Micro Biosystems Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Rapid Micro Biosystems, Inc. (RPID) Q4 2022 Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.63% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates

Reports fourth quarter 2022 commercial revenue of $4.4 million

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Guidance

LOWELL, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Cowen 43rd Annual Health Care Conference in Boston, Massachusetts.

Rapid Micro Biosystems to Participate in the Cowen 43rd Annual Health Care Conference

LOWELL, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2022 financial results prior to the market open on Friday, March 3, 2023.

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023

Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue

LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference.

Rapid Micro Biosystems to Present at 41st Annual J.P. Morgan Healthcare Conference

LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.

Rapid Micro Biosystems® Announces Publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has concluded its previously announced review of strategic alternatives.

Rapid Micro Biosystems Concludes Review of Strategic Alternatives

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Mike Beaulieu - Investor Relations Rob Spignesi - Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Stephanie Yan - Cowen Operator Hello. My name is Lisa and I will be your conference operator today.

Rapid Micro Biosystems, Inc. (RPID) Q3 2022 Earnings Call Transcript

Reports third quarter 2022 commercial revenue of $4.7 million

Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results

LOWELL, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its newest product, RMBNucleus™ Mold Alarm, which is designed to rapidly detect environmental molds in the pharmaceutical manufacturing process. RMBNucleus™ Mold Alarm is expected to be available on the Growth Direct® System before the end of 2022.

Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System

LOWELL, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its participation as a sponsor and exhibitor at the 2022 Parenteral Drug Association (“PDA”) Pharmaceutical Microbiology Conference on October 10-12, in Washington, D.C.

Rapid Micro Biosystems to Exhibit at the 2022 PDA Pharmaceutical Microbiology Conference

LOWELL, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Chief Executive Officer, Robert Spignesi, will speak at the 2022 PDA/FDA Joint Regulatory Conference on Wednesday, September 14th.

News for Rapid Micro Biosystems Stock (RPID)